Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Inflammation ; 41(4): 1460-1476, 2018 Aug.
Article in English | MEDLINE | ID: mdl-29704151

ABSTRACT

The peripheral nervous system is one of many organ systems that can be profoundly impacted in diabetes mellitus. Diabetic peripheral neuropathy has a significant negative effect on patients' quality of life as it begins with loss of limbs' sensation and may result in lower limb amputation. This investigation aimed at exploring the effect of sulforaphane on peripheral neuropathy in diabetic rats. Experimental diabetes was induced through single intraperitoneal injections of nicotinamide (50 mg/kg) and streptozotocin (52.5 mg/kg). Rats were divided into five groups. Two groups were treated with saline or sulforaphane (1 mg/kg, p.o.). Three diabetic groups were either untreated or given sulforaphane (1 mg/kg, p.o.) or pregabalin (10 mg/kg, i.p.). Two weeks after drugs' administration, biochemical, behavioral, histopathological, and immunohistochemical investigations were carried out. Treatment with sulforaphane restored animals' body weight, reduced blood glucose, glycated hemoglobin, and increased insulin levels. In parallel, it normalized motor coordination and the latency withdrawal time of tail flick test, increased the latency withdrawal time of cold allodynia test, and ameliorated histopathological changes. Treatment of sulforaphane, likewise, decreased sciatic nerve malondialdehyde, nitric oxide, interleukin-6, and matrix metalloproteinase-2 and -9 contents. Similarly, it reduced sciatic nerve DNA fragmentation and expression of cyclooxygenase-2 and nuclear factor kappa-B p65. Meanwhile, it increased sciatic nerve superoxide dismutase and interleukin-10 contents. These results reveal the neuroprotective effect of sulforaphane against peripheral neuropathy in diabetic rats possibly through modulating oxidative stress, inflammation, and extracellular matrix remodeling. Graphical Abstract Diagram that illustrates the effects of sulforaphane in treating experimental diabetic peripheral neuropathy. In NA-STZ model of diabetes mellitus, sulforaphane, restored animals' body weight, reduced blood glucose, glycated hemoglobin and increased insulin levels. In parallel, it normalized motor coordination and the latency withdrawal time of tail flick test, increased the latency withdrawal time of cold allodynia test and ameliorated histopathological changes. Treatment of sulforaphane, likewise, decreased sciatic nerve malondialdehyde, nitric oxide, interleukin-6, matrix metalloproteinase-2 and -9 contents. Similarly, it reduced sciatic nerve DNA fragmentation and expression of cyclooxygenase-2 and nuclear factor kappa-B p65. Meanwhile, it increased sciatic nerve superoxide dismutase and interleukin-10 contents.


Subject(s)
Diabetic Neuropathies/drug therapy , Extracellular Matrix/metabolism , Inflammation/drug therapy , Isothiocyanates/pharmacology , Oxidative Stress/drug effects , Animals , Anticarcinogenic Agents , Blood Glucose/drug effects , Body Weight/drug effects , Diabetes Mellitus, Experimental/complications , Diabetic Neuropathies/pathology , Extracellular Matrix/drug effects , Psychomotor Performance/drug effects , Rats , Sciatic Nerve/drug effects , Sciatic Nerve/metabolism , Sulfoxides
2.
J Neurochem ; 146(2): 173-185, 2018 07.
Article in English | MEDLINE | ID: mdl-29572844

ABSTRACT

Diabetic peripheral neuropathy is one of the most common microvascular complications that occurs with both type 1 and type 2 diabetes mellitus. It has a significant negative impact on patients' quality of life; as it starts with loss of limbs' sensation and may lead to lower limb amputation. This study aimed at investigating the effect of liraglutide on peripheral neuropathy in diabetic rats. Experimental diabetes was induced by single intraperitoneal injections of nicotinamide (50 mg/kg) and streptozotocin (52.5 mg/kg). Rats were allocated into five groups. Two groups were given saline or liraglutide (0.8 mg/kg, s.c.). Three diabetic groups were either untreated or treated with liraglutide (0.8 mg/kg, s.c.) or pregabalin (10 mg/kg, i.p.). After 2 weeks of treatment, behavioral, biochemical, histopathological, and immunohistochemical investigations were performed. Treatment with liraglutide-restored animals' body weight, normalized blood glucose, decreased glycated hemoglobin, and increased insulin levels. In parallel, it normalized motor coordination and the latency withdrawal time of both tail flick and hind paw cold allodynia tests and reversed histopathological alterations. Treatment with liraglutide also normalized malondialdehyde, matrix metalloproteinase-2 and -9 contents in sciatic nerve. Likewise, it decreased sciatic nerve nitric oxide and interleukin-6 contents, DNA fragmentation and expression of cyclooxygenase-2. Meanwhile, it increased superoxide dismutase and interleukin-10 contents in sciatic nerve. These findings indicate the neuroprotective effect of liraglutide against diabetic peripheral neuropathy probably via modulating oxidative stress, inflammation, and extracellular matrix remodeling.


Subject(s)
Diabetic Neuropathies/drug therapy , Extracellular Matrix/drug effects , Hypoglycemic Agents/therapeutic use , Inflammation/drug therapy , Liraglutide/therapeutic use , Oxidative Stress/drug effects , Animals , Antibiotics, Antineoplastic , Blood Glucose/metabolism , Body Weight/drug effects , Diabetic Neuropathies/chemically induced , Diabetic Neuropathies/complications , Disease Models, Animal , Glycated Hemoglobin/metabolism , Male , Matrix Metalloproteinases/metabolism , Niacinamide/toxicity , Pain Threshold/drug effects , Rats , Rats, Wistar , Streptozocin/toxicity , Vitamin B Complex/toxicity
3.
Can J Physiol Pharmacol ; 92(11): 945-52, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25358020

ABSTRACT

This study aimed to investigate the anti-depressant effect of hesperidin (Hsp) in streptozotocin (STZ)-induced diabetic rats. Additionally, the effect of Hsp on hyperglycaemia, oxidative stress, inflammation, brain-derived neurotrophic factor (BDNF), and brain monoamines in diabetic rats was also assessed. The Wistar rats in the experimental groups were rendered hyperglycaemic with a single dose of STZ (52.5 mg·(kg body mass)(-1), by intraperitoneal injection). The normal group received the vehicle only. Hyperglycaemic rats were treated with Hsp (25.0, 50.0, or 100.0 mg·(kg body mass)(-1)·day(-1), per oral) and fluoxetine (Flu) (5.0 mg·(kg body mass)(-1)·day(-1), per oral) 48 h after the STZ injection, for 21 consecutive days. The normal and STZ control groups received the vehicle (distilled water). Behavioral and biochemical parameters were then assessed. When Hsp was administered to the STZ-treated rats, this reversed the STZ-induced increase in immobility duration in the forced swimming test (FST) and attenuated hyperglycaemia, decreased malondialdehyde (MDA), increased reduced glutathione (GSH) decreased interleukin-6 (IL-6), and increased BDNF levels in the brain. Treatment with Hsp attenuated STZ-induced neurochemical alterations, as indicated by increased levels of monoamines in the brain, namely, norepinephrine (NE), dopamine (DA), and serotonin (5-hydroxytryptamine; 5-HT). All of these effects of Hsp were similar to those observed with the established anti-depressant Flu. This study shows that Hsp exerted anti-depressant effect in diabetic rats, which may have been partly mediated by its amelioration of hyperglycaemia as well as its anti-oxidant and anti-inflammatory activities, the enhancement of neurogenesis, and changes in the levels of monoamines in the brain.


Subject(s)
Antidepressive Agents/therapeutic use , Behavior, Animal/drug effects , Depression/drug therapy , Diabetes Mellitus, Experimental/drug therapy , Hesperidin/therapeutic use , Animals , Antidepressive Agents/pharmacology , Biogenic Monoamines/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Depression/psychology , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/psychology , Fluoxetine/pharmacology , Fluoxetine/therapeutic use , Glutathione/metabolism , Hesperidin/pharmacology , Hyperglycemia/drug therapy , Hyperglycemia/metabolism , Inflammation/drug therapy , Inflammation/metabolism , Interleukin-6/metabolism , Male , Malondialdehyde/metabolism , Oxidative Stress/drug effects , Rats, Wistar , Streptozocin
4.
PLoS One ; 8(10): e76207, 2013.
Article in English | MEDLINE | ID: mdl-24098446

ABSTRACT

Gold nanorods (GNR) within tumor microregions are characterized by their ability to absorb near IR light and emit heat in what is called photoplasmonic effect. Yet, the efficacy of nanoparticles is limited due to intratumoral tissue distribution reasons. In addition, distribution of GNRs to normal tissue might result in non specific toxicity. In the current study, we are assessing the intratumoral and tissue distribution of PEGylated GNRs on the top of its antitumor characteristics when given intravenously or intratumoral to solid tumor bearing mice and coupled with laser photoplasmonic sessions. PEGylated GNRs with a longitudinal size of less than 100 nm were prepared with aspect ratio of 4.6 showing strong surface plasmon absorption at wavelength 800 nm. Pharmacokinetics of GNR after single I.V. administration (0.1 mg/kg) showed very short systemic circulating time (less than 3 h). On the other hand, tissue distribution of I.V. GNR (0.1 mg/kg) to normal animals showed preferential deposition in spleen tissue. Repeated administration of I.V. GNR resulted in preferential accumulation in both liver and spleen tissues. In addition, I.V. administration of GNR to Ehrlich carcinoma tumor bearing mice resulted in similar tissue distribution; tumor accumulation and anti-tumor effect compared to intratumoral administration. In conclusion, the concentration of GNR achieved within tumors microregions after I.V. administration was comparable to I.T. administration and sufficient to elicit tumoral growth arrest when coupled with laser-aided photoplasmonic treatment.


Subject(s)
Carcinoma, Ehrlich Tumor/metabolism , Gold , Nanotubes , Administration, Intravenous , Animals , Carcinoma, Ehrlich Tumor/pathology , Carcinoma, Ehrlich Tumor/therapy , Disease Models, Animal , Female , Gold/chemistry , Hyperthermia, Induced , Low-Level Light Therapy , Male , Mice , Nanotubes/chemistry , Nanotubes/ultrastructure , Polyethylene Glycols/chemistry , Tissue Distribution , Tumor Burden
5.
J Ethnopharmacol ; 108(2): 236-42, 2006 Nov 24.
Article in English | MEDLINE | ID: mdl-16815658

ABSTRACT

Momordica charantia L. (MC) (Cucurbitaceae) commonly known as balsam pear, bitter gourd or karela, used in several purposes in traditional medicine is an important medicinal plant. Two sets of experiments were carried out, the first experiment indicated that the LD(50) for MC juice and alcoholic extracts were 91.9 and 362.34 mg/100g b.wt., respectively, of subcutaneously "s.c." injected mice. The toxic signs were recorded within the first 24 h post-injection. The second experiment was performed to evaluate the effect of MC juice and alcoholic extracts on blood glucose and other biochemical parameters in normal and diabetic rats. Both extracts induced a significant decrease in serum glucose levels in normal and diabetic rats. The two extracts did not show any significant effect in urea, creatinine, ALT, AST and AP in normal rat, while in diabetic rats the two extracts caused a significant decrease in serum urea, creatinine, ALT, AST, AP, cholesterol and triglyceride levels. Also, these results suggested that MC extracts possesses anti-diabetic, hepato-renal protective and hypolipidemic effect in alloxan-induced diabetic rats. Thus, MC is alternative therapy that has primarily been used for lowering blood glucose levels in patients with diabetes mellitus.


Subject(s)
Diabetes Mellitus, Experimental/prevention & control , Momordica charantia/chemistry , Plant Extracts/therapeutic use , Administration, Oral , Alkaline Phosphatase/blood , Alloxan , Animals , Anticholesteremic Agents/isolation & purification , Anticholesteremic Agents/therapeutic use , Anticholesteremic Agents/toxicity , Beverages , Blood Glucose/metabolism , Cholesterol/blood , Creatinine/blood , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Dose-Response Relationship, Drug , Ethanol , Female , Fruit , Hypoglycemia/blood , Hypoglycemia/chemically induced , Injections, Subcutaneous , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Plant Extracts/chemistry , Plant Extracts/toxicity , Rats , Rats, Sprague-Dawley , Transaminases/blood , Triglycerides/blood , Weight Gain/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...